Whistleblower exposes dangerous off-label marketing in a case the government could not have made on its own. Over $78 million returned to Medicare, and over $16 million returned to state Medicaid programs.

FCA | Boehringer Ingelheim, Robert Heiden, asthma, Micardis, Aggrenox, Atrovent, Combivent